Abstract:Background and ObjectiveCoronavirus disease 2019 is a novel disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus. It was first detected in December 2019 and has since been declared a pandemic causing millions of deaths worldwide. Therefore, there is an urgent need to develop effective therapeutics against coronavirus disease 2019. A critical step in the crosstalk between the virus and the host cell is the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to the peptidase domain of the angiotensin-converting enzyme 2 (ACE2) receptor present on the surface of host cells.MethodsAn in silico approach was employed to design a 13-amino acid peptide inhibitor (13AApi) against the RBD of the SARS-CoV-2 spike protein. Its binding specificity for RBD was confirmed by molecular docking using pyDockWEB, ClusPro 2.0, and HDOCK web servers. The stability of 13AApi and the SARS-CoV-2 spike protein complex was determined by molecular dynamics simulation using the GROMACS program while the physicochemical and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of 13AApi were determined using the ExPASy tool and pkCSM server. Finally, in vitro validation of the inhibitory activity of 13AApi against the spike protein was performed by an enzyme-linked immunosorbent assay.ResultsIn silico analyses indicated that the 13AApi could bind to the RBD of the SARS-CoV-2 spike protein at the ACE2 binding site with high affinity. In vitro experiments validated the in silico findings, showing that 13AApi could significantly block the RBD of the SARS-CoV-2 spike protein.ConclusionsBlockage of binding of the SARS-CoV-2 spike protein with ACE2 in the presence of the 13AApi may prevent virus entry into host cells. Therefore, the 13AApi can be utilized as a promising therapeutic agent to combat coronavirus disease 2019.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective therapeutic agent to combat the disease (COVID - 19) caused by the novel coronavirus (SARS - CoV - 2). Specifically, the research focuses on designing a novel therapeutic peptide that can prevent the SARS - CoV - 2 spike protein from binding to the ACE2 receptor on host cells. By preventing this crucial step, the virus can be prevented from entering the host cell, thereby inhibiting viral infection. ### Background and Objectives of the Paper - **Background**: The COVID - 19 pandemic caused by the novel coronavirus (SARS - CoV - 2) has led to millions of infections and millions of deaths worldwide, so there is an urgent need to develop effective therapeutic drugs. - **Objective**: Design a 13 - amino - acid peptide inhibitor (13AApi) that can specifically bind to the receptor - binding domain (RBD) of the SARS - CoV - 2 spike protein, thereby preventing its binding to the ACE2 receptor on the surface of host cells. ### Methods - **Computational Design**: A 13 - amino - acid peptide inhibitor was designed using computational biology tools, and its binding specificity was verified by molecular docking. - **Molecular Dynamics Simulation**: Molecular dynamics simulations were carried out using the GROMACS program to evaluate the stability of the 13AApi - SARS - CoV - 2 spike protein complex. - **Physicochemical Properties and ADMET Analysis**: The physicochemical properties and absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics of 13AApi were analyzed using ExPASy and pkCSM tools. - **In vitro Verification**: The inhibitory effect of 13AApi on the binding between the SARS - CoV - 2 spike protein and the ACE2 receptor was verified by enzyme - linked immunosorbent assay (ELISA). ### Results - **Computational Results**: 13AApi can bind to the RBD region of the SARS - CoV - 2 spike protein with high affinity, especially to the key sites that bind to the ACE2 receptor. - **Molecular Dynamics Simulation**: The simulation results show that the complex formed by 13AApi and the SARS - CoV - 2 spike protein has good stability. - **Physicochemical Properties and ADMET Analysis**: 13AApi exhibits good water - solubility, stability, and low toxicity. - **In vitro Verification**: ELISA experiments verified that 13AApi can significantly inhibit the binding between the SARS - CoV - 2 spike protein and the ACE2 receptor in vitro. ### Conclusions - **Conclusion**: As a novel therapeutic peptide, 13AApi can effectively prevent the SARS - CoV - 2 spike protein from binding to the ACE2 receptor, thereby preventing the virus from entering the host cell. This makes 13AApi a potential candidate drug for treating COVID - 19. - **Future Prospects**: Further research is required to determine the efficacy and safety of 13AApi in actual clinical applications. Through these studies, the authors hope to provide new ideas and candidate molecules for the development of therapeutic drugs against SARS - CoV - 2.

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression

Peptide S4 is an entry inhibitor of SARS-CoV-2 infection

Bionics Design of Affinity Peptide Inhibitors for SARS-CoV-2 RBD to Block SARS-CoV-2 RBD-ACE2 Interactions

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity

Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein

Computational Analysis on the ACE2-derived Peptides for Neutralizing the ACE2 Binding to the Spike Protein of SARS-CoV-2

An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade

Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells

Identification of natural peptides from "PlantPepDB" database as anti-SARS-CoV-2 agents: A protein-protein docking approach

Peptides-based Therapeutics: Emerging Potential Therapeutic Agents for COVID-19.

Anin-silicoapproach to Identify the Potential Hot Spots in SARS-CoV-2 Spike RBD to Block the Interaction with ACE2 Receptor

Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor

In silico molecular docking of SARS-CoV-2 surface proteins with microbial non-ribosomal peptides: identification of potential drugs

Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study

Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (adv. Therap. 7/2021)

Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2

A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor-Binding Domain of SARS-CoV-2

Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions Between SARS-CoV-2 Spike Protein and Human ACE2 Receptor